Takeda Pharmaceutical Co. $TAK Shares Sold by UBS Group AG

UBS Group AG trimmed its holdings in Takeda Pharmaceutical Co. (NYSE:TAK) by 30.0% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 4,123,523 shares of the company’s stock after selling 1,770,446 shares during the period. UBS Group AG’s holdings in Takeda Pharmaceutical were worth $64,286,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Private Trust Co. NA boosted its stake in Takeda Pharmaceutical by 84.7% in the 4th quarter. Private Trust Co. NA now owns 1,707 shares of the company’s stock worth $27,000 after buying an additional 783 shares during the last quarter. Northwestern Mutual Wealth Management Co. boosted its stake in Takeda Pharmaceutical by 56.3% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 3,586 shares of the company’s stock worth $55,000 after buying an additional 1,292 shares during the last quarter. Advisory Services Network LLC acquired a new stake in Takeda Pharmaceutical in the 3rd quarter worth about $74,000. Farther Finance Advisors LLC boosted its stake in Takeda Pharmaceutical by 24.5% in the 3rd quarter. Farther Finance Advisors LLC now owns 7,001 shares of the company’s stock worth $102,000 after buying an additional 1,378 shares during the last quarter. Finally, Global Trust Asset Management LLC acquired a new stake in Takeda Pharmaceutical in the 3rd quarter worth about $110,000. 9.17% of the stock is owned by institutional investors and hedge funds.

Takeda Pharmaceutical Stock Performance

Shares of NYSE:TAK opened at $16.57 on Tuesday. The company has a market cap of $52.72 billion, a P/E ratio of 69.02 and a beta of -0.06. The company has a debt-to-equity ratio of 0.56, a quick ratio of 0.65 and a current ratio of 1.19. Takeda Pharmaceutical Co. has a one year low of $12.99 and a one year high of $18.90. The business’s 50-day simple moving average is $17.94 and its 200 day simple moving average is $16.27.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on TAK shares. Wall Street Zen raised Takeda Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research note on Saturday, April 11th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Takeda Pharmaceutical in a research note on Wednesday, April 29th. Zacks Research raised Takeda Pharmaceutical from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 3rd. Morgan Stanley started coverage on Takeda Pharmaceutical in a research note on Tuesday, January 13th. They issued an “overweight” rating on the stock. Finally, Sanford C. Bernstein raised Takeda Pharmaceutical from a “market perform” rating to an “outperform” rating in a research note on Wednesday, April 8th. Two investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, Takeda Pharmaceutical has a consensus rating of “Moderate Buy”.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.